rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    BCDA
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      BioCardia (BCDA) Upgraded to Buy: Here's What You Should Know
      Nov 17Yahoo FinanceBCDA
      BioCardia, Inc. Q3 2026 Earnings Call Summary
      Nov 13Yahoo FinanceBCDA
      BioCardia Reports Third Quarter 2026 Business Highlights and Financial Results
      Nov 12Yahoo FinanceBCDA
      BioCardia to Host Q3 2026 Financial Results and Corporate Update Conference Call on November 12, 2026
      Nov 9Yahoo FinanceBCDA
      BioCardia Completes Clinical Consultation Process with Japan's PMDA for CardiAMP Cell Therapy System, Advancing Toward Submission of Marketing Approval Application
      Nov 6Yahoo FinanceBCDA
      BioCardia president and CEO Peter Altman buys $475 in BCDA shares
      Oct 21Investing.comBCDA
      FDA accepts BioCardia pre-submission for Helix catheter
      Oct 19Investing.comBCDA
      BioCardia Announces FDA Acceptance of De Novo Pre-Submission Package for Helix™ Catheter Marketing Clearance FDA Substantive Review and Meeting Expected this Quarter
      Oct 19Yahoo FinanceBCDA
      BioCardia submits revised pre-submission to FDA for Helix catheter
      Oct 1Investing.comBCDA
      BioCardia Files Revised De Novo Pre-Submission for FDA Approval of Helix™ Catheter

      SUNNYVALE, Calif., Oct. 01, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today reported it has completed its revised Pre-Submission to FDA Center for Devices and Radiological Health (CDRH) under its Q-Submission program for the approval of its Helix Catheter (“Helix”) for therapeutic and diagnostic agent delivery to the heart. In May 2026, the Company and FDA met and

      Oct 1Yahoo FinanceBCDA
      BioCardia president and CEO Peter Altman buys $1,030 in shares
      Sep 30Investing.comBCDA
      BioCardia CEO Peter Altman buys $1,995 in stock
      Sep 24Investing.comBCDA
      BioCardia targets Japan regulatory submission in Q4 2026
      Sep 23Investing.comBCDA
      BioCardia Shares Fall 10% After Hours: Here's Why - BioCardia (NASDAQ:BCDA)

      BioCardia shares fall 10% after hours after Nasdaq confirms the company regained listing compliance.

      Sep 22BenzingaBCDA
      BioCardia to Present CardiAMP Regulatory and Corporate Progress at H.C. Wainwright 28th Annual Global Investment Conference

      SUNNYVALE, Calif., Sept. 10, 2026 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that Peter Altman, Ph.D., President and Chief Executive Officer, will present at the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held at the Lotte New York Palace Hotel in New York City, September 14-16, 2026. Dr. Altman will provide an update

      Sep 10Yahoo FinanceBCDA
      BioCardia CEO Peter Altman buys $872 in company stock
      Sep 5Investing.comBCDA
      BioCardia receives FDA confirmation on Helix catheter meeting
      Aug 24Investing.comBCDA
      BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval

      SUNNYVALE, Calif., Aug. 24, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces receipt of FDA confirmation of the outcome of its Pre-Submission Meeting on the Helix Transendocardial Delivery Catheter System (Helix). FDA has reviewed and accepted the meeting minutes provided by BioCardia in May 2026 which are now considered final. This ratifies the understan

      Aug 24Yahoo FinanceBCDA
      BioCardia Receives Nasdaq Notice on Minimum Bid Price

      Tipranks Press Release.

      Aug 22The Globe and MailBCDA

      This is the newest page. Registered accounts read further back.